Oppenheimer Maintains Outperform on Eloxx Pharmaceuticals, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Eloxx Pharmaceuticals (NASDAQ:ELOX) and raises the price target from $50 to $55.
July 11, 2023 | 10:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Eloxx Pharmaceuticals and raises the price target from $50 to $55.
The news is directly related to Eloxx Pharmaceuticals. The raised price target by Oppenheimer indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100